Glioma Stem Cells

Markers, Hallmarks and Therapeutic Targeting by Metformin

Joseph Najbauer, Nikola Kraljik, P. Németh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.

Original languageEnglish
Pages (from-to)789-797
Number of pages9
JournalPathology and Oncology Research
Volume20
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Metformin
Glioma
Stem Cells
Prostatic Neoplasms
Therapeutics
Neoplasms
Therapeutic Uses
Brain Neoplasms
Type 2 Diabetes Mellitus
Radiation
Breast Neoplasms
Recurrence
Drug Therapy
Pharmaceutical Preparations

Keywords

  • Cancer stem cells
  • Glioma
  • Glioma stem cells
  • Metformin
  • Therapeutic targeting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Glioma Stem Cells : Markers, Hallmarks and Therapeutic Targeting by Metformin. / Najbauer, Joseph; Kraljik, Nikola; Németh, P.

In: Pathology and Oncology Research, Vol. 20, No. 4, 2014, p. 789-797.

Research output: Contribution to journalArticle

@article{52f2d519617f4a75a513298a0846aad3,
title = "Glioma Stem Cells: Markers, Hallmarks and Therapeutic Targeting by Metformin",
abstract = "Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.",
keywords = "Cancer stem cells, Glioma, Glioma stem cells, Metformin, Therapeutic targeting",
author = "Joseph Najbauer and Nikola Kraljik and P. N{\'e}meth",
year = "2014",
doi = "10.1007/s12253-014-9837-z",
language = "English",
volume = "20",
pages = "789--797",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Glioma Stem Cells

T2 - Markers, Hallmarks and Therapeutic Targeting by Metformin

AU - Najbauer, Joseph

AU - Kraljik, Nikola

AU - Németh, P.

PY - 2014

Y1 - 2014

N2 - Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.

AB - Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.

KW - Cancer stem cells

KW - Glioma

KW - Glioma stem cells

KW - Metformin

KW - Therapeutic targeting

UR - http://www.scopus.com/inward/record.url?scp=84919911736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919911736&partnerID=8YFLogxK

U2 - 10.1007/s12253-014-9837-z

DO - 10.1007/s12253-014-9837-z

M3 - Article

VL - 20

SP - 789

EP - 797

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 4

ER -